Inhibition of insulin‐like growth factor‐1 receptor enhances eribulin‐induced DNA damage in colorectal cancer. Issue 12 (13th September 2022)

• Record Type: Journal Article
• Authors: Yoshihiro, Tomoyasu; Ariyama, Hiroshi; Yamaguchi, Kyoko; Imajima, Takashi; Yamaga, Satoru; Tsuchihashi, Kenji; Isobe, Taichi; Kusaba, Hitoshi; Akashi, Koichi; Baba, Eishi
• Is Part Of: Cancer science. Volume 113:Issue 12(2022)
• Page Start: 4207
• Page End: 4218
• Publication Date: 2022-09-13
• Subjects: colorectal cancer -- eribulin -- IGF‐1R -- microtubule -- ROS; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.15558
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract: Microtubule targeting agents (MTAs) such as taxanes are broadly used for the treatment of patients with cancer. Although MTAs are not effective for treatment of colorectal cancer (CRC), preclinical studies suggest that a subset of patients with CRC, especially those with cancers harboring the BRAF mutation, could benefit from such agents. However, two MTAs, eribulin (Eri) and vinorelbine, have shown limited clinical efficacy. Here, we report that insulin‐like growth factor 1 receptor (IGF‐1R) signaling is involved in Eri resistance. Using CRC cell lines, we showed that Eri induces activation and subsequent translocation of IGF‐1R to the nucleus. When the activation and/or nuclear translocation of IGF‐1R was inhibited, Eri induced DNA damage and enhanced G2 /M arrest. In a xenograft model using the Eri‐resistant SW480 cell line, the combination of Eri and the IGF‐1R inhibitor linsitinib suppressed tumor growth more efficiently than either single agent. Thus, our results indicated that combination dosing with Eri and an IGF‐1R inhibitor could overcome Eri resistance and offer a therapeutic opportunity in CRC. Abstract : Nuclear translocation of IGF‐1R in SW480 following exposure to eribulin revealed by immunofluorescent staining. Nuclear translocation of IGF‐1R was not observed when exposed to the combination of eribulin and IGF‐1R inhibitor.